HAMP and acquired polycythemia vera: However, it is also possible that, because iron deficiency- and PV-related symptoms often overlap, ruxolitinib-treated patients improve symptomatically due to the consequent decreasing in phlebotomy requirements, reversing iron deficiency in general, or specifically increasing hepcidin levels, resulting in iron sequestration without exacerbating systemic iron deficiency.